---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-000527"
form_type: "8-K/A"
ticker: "AUPH"
cik: "0001600620"
company_name: "Aurinia Pharmaceuticals Inc."
filed_at: "2022-01-07T23:59:59+00:00"
generated_at: "2026-06-27T19:52:30.314757+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Aurinia reports positive 3-year AURORA 2 data for LUPKYNIS; no new safety signals

## Summary
- eGFR stable over 36 months; +2.7 mL/min vs control from baseline.
- Serious AE rates: 19% voclosporin vs 24% control; 0 deaths in voclosporin arm vs 4 in placebo.
- Mean UPCR lower in voclosporin group at all time points over 3 years.
- Withdrawal rate: 12.9% voclosporin vs 15.0% control; drug well tolerated.
- AURORA 2 enrolled 216 LN patients; 90 voclosporin and 78 control completed 36 months.

## SEC filing metadata
- accession: 0001628280-22-000527
- form_type: 8-K/A
- ticker: AUPH
- cik: 0001600620
- company_name: Aurinia Pharmaceuticals Inc.
- filed_at: 2022-01-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1600620/000162828022000527/0001628280-22-000527-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1600620/000162828022000527/auph-20211209.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-000527
- JSON: https://secwatch.observer/filing/0001628280-22-000527.json
- Plain text: https://secwatch.observer/filing/0001628280-22-000527.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.